EU industry: new PV fee plan better, but still much room for improvement
This article was originally published in Scrip
Groups representing the innovator and generic pharmaceutical industries in Europe have welcomed the changes made by the European Commission to its original plans for a pharmacovigilance fee system, but say that there are still major problems with the proposal.
You may also be interested in...
Roche plans to appeal against a penalty imposed by the Romanian competition authorities for implementing strategies that were said to delay the entry of competing biosimilar and generic products.
The EU association representing parallel traders says cheaper parallel imports are vital in keeping medicines affordable for member states.
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.